NCT05176314

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants

A Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Single and Multiple Doses of Pirtobrutinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Loxo Oncology, Inc. · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to determine the effect of pirtobrutinib on the levels of rosuvastatin in the blood stream in healthy participants. This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with pirtobrutinib in healthy participants. This study will last up to approximately 26 days excluding screening period.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Rosuvastatin	Administered Orally.
DRUG	Pirtobrutinib	Administered Orally.

Timeline

• Start date: 2022-01-11
• Primary completion: 2022-04-20
• Completion: 2022-04-20
• First posted: 2022-01-04
• Last updated: 2024-09-19
• Results posted: 2024-09-19

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study